A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.
- Males and females ≥ 18 years of age
- Histologically or cytologically confirmed advanced solid tumor malignancy, refractory or relapsed from prior therapy, or for whom no alternative therapy is available
- At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (≤ Grade 1)
- Archival tumor sample available, or be willing to undergo a fresh tumor biopsy, prior to study
- At least one measurable disease site that meets target lesion requirements
- Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2
- Life expectancy of ≥ 3 months
- Adequate hematologic parameters without ongoing transfusional support:
- Negative serum pregnancy test
- Ability to provide written informed consent
- Expansion Phase: P-cadherin positive tumor expression
- Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ≥ 28 days has elapsed from last dose to study treatment.
- Prior radiation to > 30% of the red marrow or to maximal tolerable level for any organ
- Serious cardiac condition within the last 6 months
- Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of antimicrobials that are considered to be essential for care of the patient
- History of retinal degenerative disease, history of uveitis, history of retinal vein occlusion (RVO), or any eye condition that would be considered a risk factor for RVO or has medically relevant abnormalities identified on screening ophthalmologic examination
- Active central nervous system (CNS) malignant disease in subjects with a history of CNS malignancy. Subjects with stable, prior, or currently treated brain metastases are allowed.
- Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
- Known autoimmune disease
- Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study
- Corticosteroid use within 2 weeks of study treatment
- Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or confound the interpretation of study results
- Pregnant or breast-feeding
Locations & Contacts
Name Not Available
Contact: Vivek Subbiah
Trial Phase & Type
Fujifilm Pharmaceuticals U.S.A., Inc.
Secondary IDs NCI-2015-01552
Clinicaltrials.gov ID NCT02454010